Table 2 LDCA and other factors associated with risk of 90-day mortality in ACLF patients

LDCA

 No

1

1

1

1

1

 Yes

2.62 (1.79–3.84)***

1.07 (0.66–1.73)

1.49 (0.95–2.36)

1.41 (0.90–2.22)

1.05 (0.65–1.72)

Age (years)

1.03 (1.01–1.05)***

0.99 (0.97–1.02)

0.97 (0.94–0.99)**

1.02 (1.00–1.04)

1.01 (0.99–1.03)

Gender

 Male

1

1

1

1

1

 Female

1.84 (1.15–2.94)*

1.24 (0.73–2.08)

1.04 (0.62–1.76)

1.25 (0.74–2.09)

1.81 (1.07–3.08)*

Liver cirrhosis

 No

1

1

1

1

1

 Yes

2.51 (1.37–4.57)**

1.66 (0.90–3.08)

2.14 (1.17–3.95)*

2.20 (1.19–4.06)*

1.97 (1.07–3.65)*

HBV DNA (log10 IU/mL)

0.98 (0.89–1.09)

1.02 (0.92–1.13)

1.00 (0.90–1.12)

1.00 (0.90–1.12)

1.01 (0.90–1.13)

Etiology

 HBV infection only

1

1

1

1

1

 HBV infection plus other causes^■

0.93 (0.60–1.45)

1.07 (0.68–1.69)

1.07 (0.68–1.68)

1.06 (0.67–1.67)

0.82 (0.51–1.29)

Comorbidity^◆

 No

1

1

1

1

1

 Yes

1.86 (1.20–2.90)**

1.74 (1.05–2.87)*

1.56 (0.96–2.55)

1.60 (0.98–2.61)

1.75 (1.06–2.90)*

Disease severity

 COSSH ACLFscore

2.78 (2.31–3.34)***

2.72 (2.17–3.40)***

–

–

–

 CLIF-C ACLF score

1.13 (1.09–1.16)***

–

1.15 (1.10–1.19)***

–

–

 AARCACLF score

1.60 (1.41–1.82)***

–

–

1.59 (1.38–1.83)***

–

 MELD score

1.16 (1.12–1.20)***

–

–

–

1.17 (1.12–1.22)***